Skip to main content

Advertisement

Figure 1 | Journal of Translational Medicine

Figure 1

From: Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Figure 1

Mean serum concentration-time profiles of EMD 273063. Mean serum concentration-time profiles after daily 4-h infusions of EMD 273063, days 1–3 by cycle and treatment. Depicted are the mean serum concentrations (linear scale with SD) for patients in cycle 1 at dose 4 mg/m2 (n = 9, closed circles), cycle 2 at dose 4 mg/m2 (n = 7, closed triangles), and the one (n = 1, open triangles) patient who received cycle 2 at dose 2 mg/m2. Blood samples for PK analysis were drawn during cycles 1 and 2 as pre-dose and post-dose samples (2, 4, 5, 6, 8, 12, and 24 h, with the 12-h sample not taken in cycle 2). The 4-h time point corresponded to the end of infusion (EOI). Additional pre-dose and EOI samples were taken on days 2 and 3 of both cycles. An ELISA was used to measure EMD 273063 levels.

Back to article page